1 Spinal Muscular Atrophy Medicine Market Overview 1.1 Product Overview and Scope of Spinal Muscular Atrophy Medicine 1.2 Spinal Muscular Atrophy Medicine Segment by Type 1.2.1 Global Spinal Muscular Atrophy Medicine Sales Growth Rate Comparison by Type (2021-2027) 1.2.2 LMI-070 1.2.3 ND-602 1.2.4 NT-1654 1.2.5 Nusinersen 1.2.6 NXD-30001 1.2.7 Others 1.3 Spinal Muscular Atrophy Medicine Segment by Application 1.3.1 Spinal Muscular Atrophy Medicine Sales Comparison by Application: (2021-2027) 1.3.2 Hospital 1.3.3 Clinic 1.3.4 Others 1.4 Global Spinal Muscular Atrophy Medicine Market Size Estimates and Forecasts 1.4.1 Global Spinal Muscular Atrophy Medicine Revenue 2016-2027 1.4.2 Global Spinal Muscular Atrophy Medicine Sales 2016-2027 1.4.3 Spinal Muscular Atrophy Medicine Market Size by Region: 2016 Versus 2021 Versus 2027 2 Spinal Muscular Atrophy Medicine Market Competition by Manufacturers 2.1 Global Spinal Muscular Atrophy Medicine Sales Market Share by Manufacturers (2016-2021) 2.2 Global Spinal Muscular Atrophy Medicine Revenue Market Share by Manufacturers (2016-2021) 2.3 Global Spinal Muscular Atrophy Medicine Average Price by Manufacturers (2016-2021) 2.4 Manufacturers Spinal Muscular Atrophy Medicine Manufacturing Sites, Area Served, Product Type 2.5 Spinal Muscular Atrophy Medicine Market Competitive Situation and Trends 2.5.1 Spinal Muscular Atrophy Medicine Market Concentration Rate 2.5.2 The Global Top 5 and Top 10 Largest Spinal Muscular Atrophy Medicine Players Market Share by Revenue 2.5.3 Global Spinal Muscular Atrophy Medicine Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans 3 Spinal Muscular Atrophy Medicine Retrospective Market Scenario by Region 3.1 Global Spinal Muscular Atrophy Medicine Retrospective Market Scenario in Revenue by Region: 2016-2021 3.2 Global Spinal Muscular Atrophy Medicine Retrospective Market Scenario in Sales by Region: 2016-2021 3.3 North America Spinal Muscular Atrophy Medicine Market Facts & Figures by Country 3.3.1 North America Spinal Muscular Atrophy Medicine Sales by Country 3.3.2 North America Spinal Muscular Atrophy Medicine Revenue by Country 3.3.3 U.S. 3.3.4 Canada 3.4 Europe Spinal Muscular Atrophy Medicine Market Facts & Figures by Country 3.4.1 Europe Spinal Muscular Atrophy Medicine Sales by Country 3.4.2 Europe Spinal Muscular Atrophy Medicine Revenue by Country 3.4.3 Germany 3.4.4 France 3.4.5 U.K. 3.4.6 Italy 3.4.7 Russia 3.5 Asia Pacific Spinal Muscular Atrophy Medicine Market Facts & Figures by Region 3.5.1 Asia Pacific Spinal Muscular Atrophy Medicine Sales by Region 3.5.2 Asia Pacific Spinal Muscular Atrophy Medicine Revenue by Region 3.5.3 China 3.5.4 Japan 3.5.5 South Korea 3.5.6 India 3.5.7 Australia 3.5.8 Taiwan 3.5.9 Indonesia 3.5.10 Thailand 3.5.11 Malaysia 3.5.12 Philippines 3.5.13 Vietnam 3.6 Latin America Spinal Muscular Atrophy Medicine Market Facts & Figures by Country 3.6.1 Latin America Spinal Muscular Atrophy Medicine Sales by Country 3.6.2 Latin America Spinal Muscular Atrophy Medicine Revenue by Country 3.6.3 Mexico 3.6.4 Brazil 3.6.5 Argentina 3.7 Middle East and Africa Spinal Muscular Atrophy Medicine Market Facts & Figures by Country 3.7.1 Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Country 3.7.2 Middle East and Africa Spinal Muscular Atrophy Medicine Revenue by Country 3.7.3 Turkey 3.7.4 Saudi Arabia 3.7.5 U.A.E 4 Global Spinal Muscular Atrophy Medicine Historic Market Analysis by Type 4.1 Global Spinal Muscular Atrophy Medicine Sales Market Share by Type (2016-2021) 4.2 Global Spinal Muscular Atrophy Medicine Revenue Market Share by Type (2016-2021) 4.3 Global Spinal Muscular Atrophy Medicine Price by Type (2016-2021) 5 Global Spinal Muscular Atrophy Medicine Historic Market Analysis by Application 5.1 Global Spinal Muscular Atrophy Medicine Sales Market Share by Application (2016-2021) 5.2 Global Spinal Muscular Atrophy Medicine Revenue Market Share by Application (2016-2021) 5.3 Global Spinal Muscular Atrophy Medicine Price by Application (2016-2021) 6 Key Companies Profiled 6.1 Astellas Pharma Inc. 6.1.1 Astellas Pharma Inc. Corporation Information 6.1.2 Astellas Pharma Inc. Description and Business Overview 6.1.3 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2016-2021) 6.1.4 Astellas Pharma Inc. Product Portfolio 6.1.5 Astellas Pharma Inc. Recent Developments/Updates 6.2 AveXis, Inc. 6.2.1 AveXis, Inc. Corporation Information 6.2.2 AveXis, Inc. Description and Business Overview 6.2.3 AveXis, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2016-2021) 6.2.4 AveXis, Inc. Product Portfolio 6.2.5 AveXis, Inc. Recent Developments/Updates 6.3 Bioblast Pharma Ltd. 6.3.1 Bioblast Pharma Ltd. Corporation Information 6.3.2 Bioblast Pharma Ltd. Description and Business Overview 6.3.3 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2016-2021) 6.3.4 Bioblast Pharma Ltd. Product Portfolio 6.3.5 Bioblast Pharma Ltd. Recent Developments/Updates 6.4 Cytokinetics, Inc. 24 6.4.1 Cytokinetics, Inc. 24 Corporation Information 6.4.2 Cytokinetics, Inc. 24 Description and Business Overview 6.4.3 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2016-2021) 6.4.4 Cytokinetics, Inc. 24 Product Portfolio 6.4.5 Cytokinetics, Inc. 24 Recent Developments/Updates 6.5 F. Hoffmann-La Roche Ltd. 6.5.1 F. Hoffmann-La Roche Ltd. Corporation Information 6.5.2 F. Hoffmann-La Roche Ltd. Description and Business Overview 6.5.3 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2016-2021) 6.5.4 F. Hoffmann-La Roche Ltd. Product Portfolio 6.5.5 F. Hoffmann-La Roche Ltd. Recent Developments/Updates 6.6 Genethon 6.6.1 Genethon Corporation Information 6.6.2 Genethon Description and Business Overview 6.6.3 Genethon Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2016-2021) 6.6.4 Genethon Product Portfolio 6.6.5 Genethon Recent Developments/Updates 6.7 Genzyme Corporation 6.6.1 Genzyme Corporation Corporation Information 6.6.2 Genzyme Corporation Description and Business Overview 6.6.3 Genzyme Corporation Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2016-2021) 6.4.4 Genzyme Corporation Product Portfolio 6.7.5 Genzyme Corporation Recent Developments/Updates 6.8 GMP-Orphan SAS 6.8.1 GMP-Orphan SAS Corporation Information 6.8.2 GMP-Orphan SAS Description and Business Overview 6.8.3 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2016-2021) 6.8.4 GMP-Orphan SAS Product Portfolio 6.8.5 GMP-Orphan SAS Recent Developments/Updates 6.9 Ionis Pharmaceuticals, Inc. 6.9.1 Ionis Pharmaceuticals, Inc. Corporation Information 6.9.2 Ionis Pharmaceuticals, Inc. Description and Business Overview 6.9.3 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2016-2021) 6.9.4 Ionis Pharmaceuticals, Inc. Product Portfolio 6.9.5 Ionis Pharmaceuticals, Inc. Recent Developments/Updates 6.10 Longevity Biotech, Inc 6.10.1 Longevity Biotech, Inc Corporation Information 6.10.2 Longevity Biotech, Inc Description and Business Overview 6.10.3 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2016-2021) 6.10.4 Longevity Biotech, Inc Product Portfolio 6.10.5 Longevity Biotech, Inc Recent Developments/Updates 6.11 Neurodyn Inc. 6.11.1 Neurodyn Inc. Corporation Information 6.11.2 Neurodyn Inc. Spinal Muscular Atrophy Medicine Description and Business Overview 6.11.3 Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2016-2021) 6.11.4 Neurodyn Inc. Product Portfolio 6.11.5 Neurodyn Inc. Recent Developments/Updates 6.12 Neurotune AG 6.12.1 Neurotune AG Corporation Information 6.12.2 Neurotune AG Spinal Muscular Atrophy Medicine Description and Business Overview 6.12.3 Neurotune AG Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2016-2021) 6.12.4 Neurotune AG Product Portfolio 6.12.5 Neurotune AG Recent Developments/Updates 6.13 Novartis AG 6.13.1 Novartis AG Corporation Information 6.13.2 Novartis AG Spinal Muscular Atrophy Medicine Description and Business Overview 6.13.3 Novartis AG Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2016-2021) 6.13.4 Novartis AG Product Portfolio 6.13.5 Novartis AG Recent Developments/Updates 6.14 Sarepta Therapeutics, Inc. 6.14.1 Sarepta Therapeutics, Inc. Corporation Information 6.14.2 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Description and Business Overview 6.14.3 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2016-2021) 6.14.4 Sarepta Therapeutics, Inc. Product Portfolio 6.14.5 Sarepta Therapeutics, Inc. Recent Developments/Updates 6.15 Voyager Therapeutics, Inc. 6.15.1 Voyager Therapeutics, Inc. Corporation Information 6.15.2 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Description and Business Overview 6.15.3 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2016-2021) 6.15.4 Voyager Therapeutics, Inc. Product Portfolio 6.15.5 Voyager Therapeutics, Inc. Recent Developments/Updates 6.16 Vybion, Inc. 6.16.1 Vybion, Inc. Corporation Information 6.16.2 Vybion, Inc. Spinal Muscular Atrophy Medicine Description and Business Overview 6.16.3 Vybion, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2016-2021) 6.16.4 Vybion, Inc. Product Portfolio 6.16.5 Vybion, Inc. Recent Developments/Updates 6.17 WAVE Life Sciences Ltd. 6.17.1 WAVE Life Sciences Ltd. Corporation Information 6.17.2 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Description and Business Overview 6.17.3 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2016-2021) 6.17.4 WAVE Life Sciences Ltd. Product Portfolio 6.17.5 WAVE Life Sciences Ltd. Recent Developments/Updates 7 Spinal Muscular Atrophy Medicine Manufacturing Cost Analysis 7.1 Spinal Muscular Atrophy Medicine Key Raw Materials Analysis 7.1.1 Key Raw Materials 7.1.2 Key Suppliers of Raw Materials 7.2 Proportion of Manufacturing Cost Structure 7.3 Manufacturing Process Analysis of Spinal Muscular Atrophy Medicine 7.4 Spinal Muscular Atrophy Medicine Industrial Chain Analysis 8 Marketing Channel, Distributors and Customers 8.1 Marketing Channel 8.2 Spinal Muscular Atrophy Medicine Distributors List 8.3 Spinal Muscular Atrophy Medicine Customers 9 Spinal Muscular Atrophy Medicine Market Dynamics 9.1 Spinal Muscular Atrophy Medicine Industry Trends 9.2 Spinal Muscular Atrophy Medicine Growth Drivers 9.3 Spinal Muscular Atrophy Medicine Market Challenges 9.4 Spinal Muscular Atrophy Medicine Market Restraints 10 Global Market Forecast 10.1 Spinal Muscular Atrophy Medicine Market Estimates and Projections by Type 10.1.1 Global Forecasted Sales of Spinal Muscular Atrophy Medicine by Type (2022-2027) 10.1.2 Global Forecasted Revenue of Spinal Muscular Atrophy Medicine by Type (2022-2027) 10.2 Spinal Muscular Atrophy Medicine Market Estimates and Projections by Application 10.2.1 Global Forecasted Sales of Spinal Muscular Atrophy Medicine by Application (2022-2027) 10.2.2 Global Forecasted Revenue of Spinal Muscular Atrophy Medicine by Application (2022-2027) 10.3 Spinal Muscular Atrophy Medicine Market Estimates and Projections by Region 10.3.1 Global Forecasted Sales of Spinal Muscular Atrophy Medicine by Region (2022-2027) 10.3.2 Global Forecasted Revenue of Spinal Muscular Atrophy Medicine by Region (2022-2027) 11 Research Finding and Conclusion 12 Methodology and Data Source 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Author List 12.4 Disclaimer

List of Tables Table 1. Global Spinal Muscular Atrophy Medicine Sales (K Pcs) Growth Rate Comparison by Type (2021-2027) Table 2. Global Spinal Muscular Atrophy Medicine Sales (K Pcs) Comparison by Application (2021-2027) Table 3. Global Spinal Muscular Atrophy Medicine Market Size by Region (US$ Million) (2016 VS 2021 VS 2027) Table 4. Key Manufacturers Spinal Muscular Atrophy Medicine Covered in This Study Table 5. Global Spinal Muscular Atrophy Medicine Sales (K Pcs) of Key Manufacturers (2016-2021) Table 6. Global Spinal Muscular Atrophy Medicine Sales Share by Manufacturers (2016-2021) Table 7. Global Spinal Muscular Atrophy Medicine Revenue (US$ Million) by Manufacturers (2016-2021) Table 8. Global Spinal Muscular Atrophy Medicine Revenue Share by Manufacturers (2016-2021) Table 9. Global Market Spinal Muscular Atrophy Medicine Average Price (USD/Pcs) of Key Manufacturers (2016-2021) Table 10. Manufacturers Spinal Muscular Atrophy Medicine Manufacturing Sites and Area Served Table 11. Manufacturers Spinal Muscular Atrophy Medicine Product Type Table 12. Global Spinal Muscular Atrophy Medicine Manufacturers Market Concentration Ratio (CR5 and HHI) Table 13. Global Spinal Muscular Atrophy Medicine by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Spinal Muscular Atrophy Medicine as of 2020) Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans Table 15. Global Spinal Muscular Atrophy Medicine Sales by Region (2016-2021) & (K Pcs) Table 16. Global Spinal Muscular Atrophy Medicine Sales Market Share by Region (2016-2021) Table 17. Global Spinal Muscular Atrophy Medicine Revenue by Region (2016-2021) & (US$ Million) Table 18. North America Spinal Muscular Atrophy Medicine Sales by Country (2016-2021) & (K Pcs) Table 19. North America Spinal Muscular Atrophy Medicine Sales Market Share by Country (2016-2021) Table 20. North America Spinal Muscular Atrophy Medicine Revenue by Country (2016-2021) & (US$ Million) Table 21. North America Spinal Muscular Atrophy Medicine Revenue Market Share by Country (2016-2021) Table 22. Europe Spinal Muscular Atrophy Medicine Sales by Country (2016-2021) & (K Pcs) Table 23. Europe Spinal Muscular Atrophy Medicine Sales Market Share by Country (2016-2021) Table 24. Europe Spinal Muscular Atrophy Medicine Revenue by Country (2016-2021) & (US$ Million) Table 25. Europe Spinal Muscular Atrophy Medicine Revenue Market Share by Country (2016-2021) Table 26. Asia Pacific Spinal Muscular Atrophy Medicine Sales by Region (2016-2021) & (K Pcs) Table 27. Asia Pacific Spinal Muscular Atrophy Medicine Sales Market Share by Region (2016-2021) Table 28. Asia Pacific Spinal Muscular Atrophy Medicine Revenue by Region (2016-2021) & (US$ Million) Table 29. Asia Pacific Spinal Muscular Atrophy Medicine Revenue Market Share by Region (2016-2021) Table 30. Latin America Spinal Muscular Atrophy Medicine Sales by Country (2016-2021) & (K Pcs) Table 31. Latin America Spinal Muscular Atrophy Medicine Sales Market Share by Country (2016-2021) Table 32. Latin America Spinal Muscular Atrophy Medicine Revenue by Country (2016-2021) & (US$ Million) Table 33. Latin America Spinal Muscular Atrophy Medicine Revenue Market Share by Country (2016-2021) Table 34. Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Country (2016-2021) & (K Pcs) Table 35. Middle East and Africa Spinal Muscular Atrophy Medicine Sales Market Share by Country (2016-2021) Table 36. Middle East and Africa Spinal Muscular Atrophy Medicine Revenue by Country (2016-2021) & (US$ Million) Table 37. Middle East and Africa Spinal Muscular Atrophy Medicine Revenue Market Share by Country (2016-2021) Table 38. Global Spinal Muscular Atrophy Medicine Sales (K Pcs) by Type (2016-2021) Table 39. Global Spinal Muscular Atrophy Medicine Sales Market Share by Type (2016-2021) Table 40. Global Spinal Muscular Atrophy Medicine Revenue (Million US$) by Type (2016-2021) Table 41. Global Spinal Muscular Atrophy Medicine Revenue Share by Type (2016-2021) Table 42. Global Spinal Muscular Atrophy Medicine Price (USD/Pcs) by Type (2016-2021) Table 43. Global Spinal Muscular Atrophy Medicine Sales (K Pcs) by Application (2016-2021) Table 44. Global Spinal Muscular Atrophy Medicine Sales Market Share by Application (2016-2021) Table 45. Global Spinal Muscular Atrophy Medicine Revenue (Million US$) by Application (2016-2021) Table 46. Global Spinal Muscular Atrophy Medicine Revenue Share by Application (2016-2021) Table 47. Global Spinal Muscular Atrophy Medicine Price (USD/Pcs) by Application (2016-2021) Table 48. Astellas Pharma Inc. Corporation Information Table 49. Astellas Pharma Inc. Description and Business Overview Table 50. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 51. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product Table 52. Astellas Pharma Inc. Recent Developments/Updates Table 53. AveXis, Inc. Corporation Information Table 54. AveXis, Inc. Description and Business Overview Table 55. AveXis, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 56. AveXis, Inc. Spinal Muscular Atrophy Medicine Product Table 57. AveXis, Inc. Recent Developments/Updates Table 58. Bioblast Pharma Ltd. Corporation Information Table 59. Bioblast Pharma Ltd. Description and Business Overview Table 60. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 61. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product Table 62. Bioblast Pharma Ltd. Recent Developments/Updates Table 63. Cytokinetics, Inc. 24 Corporation Information Table 64. Cytokinetics, Inc. 24 Description and Business Overview Table 65. Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 66. Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Product Table 67. Cytokinetics, Inc. 24 Recent Developments/Updates Table 68. F. Hoffmann-La Roche Ltd. Corporation Information Table 69. F. Hoffmann-La Roche Ltd. Description and Business Overview Table 70. F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 71. F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product Table 72. F. Hoffmann-La Roche Ltd. Recent Developments/Updates Table 73. Genethon Corporation Information Table 74. Genethon Description and Business Overview Table 75. Genethon Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 76. Genethon Spinal Muscular Atrophy Medicine Product Table 77. Genethon Recent Developments/Updates Table 78. Genzyme Corporation Corporation Information Table 79. Genzyme Corporation Description and Business Overview Table 80. Genzyme Corporation Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 81. Genzyme Corporation Spinal Muscular Atrophy Medicine Product Table 82. Genzyme Corporation Recent Developments/Updates Table 83. GMP-Orphan SAS Corporation Information Table 84. GMP-Orphan SAS Description and Business Overview Table 85. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 86. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product Table 87. GMP-Orphan SAS Recent Developments/Updates Table 88. Ionis Pharmaceuticals, Inc. Corporation Information Table 89. Ionis Pharmaceuticals, Inc. Description and Business Overview Table 90. Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 91. Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Product Table 92. Ionis Pharmaceuticals, Inc. Recent Developments/Updates Table 93. Longevity Biotech, Inc Corporation Information Table 94. Longevity Biotech, Inc Description and Business Overview Table 95. Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 96. Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Product Table 97. Longevity Biotech, Inc Recent Developments/Updates Table 98. Neurodyn Inc. Corporation Information Table 99. Neurodyn Inc. Description and Business Overview Table 100. Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 101. Neurodyn Inc. Spinal Muscular Atrophy Medicine Product Table 102. Neurodyn Inc. Recent Developments/Updates Table 103. Neurotune AG Corporation Information Table 104. Neurotune AG Description and Business Overview Table 105. Neurotune AG Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 106. Neurotune AG Spinal Muscular Atrophy Medicine Product Table 107. Neurotune AG Recent Developments/Updates Table 108. Novartis AG Corporation Information Table 109. Novartis AG Description and Business Overview Table 110. Novartis AG Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 111. Novartis AG Spinal Muscular Atrophy Medicine Product Table 112. Novartis AG Recent Developments/Updates Table 113. Sarepta Therapeutics, Inc. Corporation Information Table 114. Sarepta Therapeutics, Inc. Description and Business Overview Table 115. Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 116. Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Table 117. Sarepta Therapeutics, Inc. Recent Developments/Updates Table 118. Voyager Therapeutics, Inc. Corporation Information Table 119. Voyager Therapeutics, Inc. Description and Business Overview Table 120. Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 121. Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Table 122. Voyager Therapeutics, Inc. Recent Developments/Updates Table 123. Vybion, Inc. Corporation Information Table 124. Vybion, Inc. Description and Business Overview Table 125. Vybion, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 126. Vybion, Inc. Spinal Muscular Atrophy Medicine Product Table 127. Vybion, Inc. Recent Developments/Updates Table 128. WAVE Life Sciences Ltd. Corporation Information Table 129. WAVE Life Sciences Ltd. Description and Business Overview Table 130. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 131. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product Table 132. WAVE Life Sciences Ltd. Recent Developments/Updates Table 133. Production Base and Market Concentration Rate of Raw Material Table 134. Key Suppliers of Raw Materials Table 135. Spinal Muscular Atrophy Medicine Distributors List Table 136. Spinal Muscular Atrophy Medicine Customers List Table 137. Spinal Muscular Atrophy Medicine Market Trends Table 138. Spinal Muscular Atrophy Medicine Growth Drivers Table 139. Spinal Muscular Atrophy Medicine Market Restraints Table 140. Global Spinal Muscular Atrophy Medicine Sales Forecast by Type (2022-2027) & (K Pcs) Table 141. Global Spinal Muscular Atrophy Medicine Sales Market Share Forecast by Type (2022-2027) Table 142. Global Spinal Muscular Atrophy Medicine Revenue Forecast by Type (2022-2027) & (US$ Million) Table 143. Global Spinal Muscular Atrophy Medicine Revenue Market Share Forecast by Type (2022-2027) Table 144. Global Spinal Muscular Atrophy Medicine Sales Forecast by Application (2022-2027) & (K Pcs) Table 145. Global Spinal Muscular Atrophy Medicine Sales Market Share Forecast by Application (2022-2027) Table 146. Global Spinal Muscular Atrophy Medicine Revenue Forecast by Application (2022-2027) & (US$ Million) Table 147. Global Spinal Muscular Atrophy Medicine Revenue Market Share Forecast by Application (2022-2027) Table 148. Global Spinal Muscular Atrophy Medicine Sales Forecast by Region (2022-2027) & (K Pcs) Table 149. Global Spinal Muscular Atrophy Medicine Sales Market Share Forecast by Region (2022-2027) Table 150. Global Spinal Muscular Atrophy Medicine Revenue Forecast by Region (2022-2027) & (US$ Million) Table 151. Global Spinal Muscular Atrophy Medicine Revenue Market Share Forecast by Region (2022-2027) Table 152. Research Programs/Design for This Report Table 153. Key Data Information from Secondary Sources Table 154. Key Data Information from Primary Sources List of Figures Figure 1. Product Picture of Spinal Muscular Atrophy Medicine Figure 2. Global Spinal Muscular Atrophy Medicine Market Share by Type in 2020 & 2027 Figure 3. LMI-070 Product Picture Figure 4. ND-602 Product Picture Figure 5. NT-1654 Product Picture Figure 6. Nusinersen Product Picture Figure 7. NXD-30001 Product Picture Figure 8. Others Product Picture Figure 9. Global Spinal Muscular Atrophy Medicine Market Share by Application in 2020 & 2027 Figure 10. Hospital Figure 11. Clinic Figure 12. Others Figure 13. Global Spinal Muscular Atrophy Medicine Revenue, (US$ Million), 2016 VS 2021 VS 2027 Figure 14. Global Spinal Muscular Atrophy Medicine Market Size 2016-2027 (US$ Million) Figure 15. Global Spinal Muscular Atrophy Medicine Sales 2016-2027 (K Pcs) Figure 16. Global Spinal Muscular Atrophy Medicine Market Size Market Share by Region: 2016 VS 20210 VS 2027 Figure 17. Spinal Muscular Atrophy Medicine Sales Share by Manufacturers in 2020 Figure 18. Global Spinal Muscular Atrophy Medicine Revenue Share by Manufacturers in 2020 Figure 19. The Global 5 and 10 Largest Spinal Muscular Atrophy Medicine Players: Market Share by Revenue in 2020 Figure 20. Spinal Muscular Atrophy Medicine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021 Figure 21. Global Spinal Muscular Atrophy Medicine Sales Market Share by Region (2016-2021) Figure 22. Global Spinal Muscular Atrophy Medicine Sales Market Share by Region in 2020 Figure 23. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Region (2016-2021) Figure 24. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Region in 2020 Figure 25. U.S. Spinal Muscular Atrophy Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 26. Canada Spinal Muscular Atrophy Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 27. Germany Spinal Muscular Atrophy Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 28. France Spinal Muscular Atrophy Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 29. U.K. Spinal Muscular Atrophy Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 30. Italy Spinal Muscular Atrophy Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 31. Russia Spinal Muscular Atrophy Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 32. China Spinal Muscular Atrophy Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 33. Japan Spinal Muscular Atrophy Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 34. South Korea Spinal Muscular Atrophy Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 35. India Spinal Muscular Atrophy Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 36. Australia Spinal Muscular Atrophy Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 37. Taiwan Spinal Muscular Atrophy Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 38. Indonesia Spinal Muscular Atrophy Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 39. Thailand Spinal Muscular Atrophy Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 40. Malaysia Spinal Muscular Atrophy Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 41. Philippines Spinal Muscular Atrophy Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 42. Vietnam Spinal Muscular Atrophy Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 43. Mexico Spinal Muscular Atrophy Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 44. Brazil Spinal Muscular Atrophy Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 45. Argentina Spinal Muscular Atrophy Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 46. Turkey Spinal Muscular Atrophy Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 47. Saudi Arabia Spinal Muscular Atrophy Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 48. U.A.E Spinal Muscular Atrophy Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 49. Sales Market Share of Spinal Muscular Atrophy Medicine by Type (2016-2021) Figure 50. Sales Market Share of Spinal Muscular Atrophy Medicine by Application (2016-2021) Figure 51. Sales Market Share of Spinal Muscular Atrophy Medicine by Application in 2020 Figure 52. Revenue Share of Spinal Muscular Atrophy Medicine by Application (2016-2021) Figure 53. Revenue Share of Spinal Muscular Atrophy Medicine by Application in 2020 Figure 54. Manufacturing Cost Structure of Spinal Muscular Atrophy Medicine Figure 55. Manufacturing Process Analysis of Spinal Muscular Atrophy Medicine Figure 56. Spinal Muscular Atrophy Medicine Industrial Chain Analysis Figure 57. Channels of Distribution Figure 58. Distributors Profiles Figure 59. Bottom-up and Top-down Approaches for This Report Figure 60. Data Triangulation Figure 61. Key Executives Interviewed